27Mar/24
Overcoming Resistance: Enhancing CAR-T Therapy for AML with TP53 Mutations
Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…